1. Home
  2. JHG vs BLCO Comparison

JHG vs BLCO Comparison

Compare JHG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janus Henderson Group plc

JHG

Janus Henderson Group plc

HOLD

Current Price

$45.60

Market Cap

6.8B

Sector

Finance

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.90

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JHG
BLCO
Founded
1934
1853
Country
United Kingdom
Canada
Employees
N/A
N/A
Industry
Investment Managers
Ophthalmic Goods
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
JHG
BLCO
Price
$45.60
$16.90
Analyst Decision
Buy
Hold
Analyst Count
8
14
Target Price
$47.88
$17.31
AVG Volume (30 Days)
811.3K
408.9K
Earning Date
01-30-2026
10-29-2025
Dividend Yield
3.52%
N/A
EPS Growth
33.81
N/A
EPS
3.39
N/A
Revenue
$2,663,300,000.00
$4,976,000,000.00
Revenue This Year
$10.79
$8.08
Revenue Next Year
$6.90
$5.77
P/E Ratio
$13.42
N/A
Revenue Growth
14.14
6.23
52 Week Low
$28.26
$10.45
52 Week High
$49.42
$18.99

Technical Indicators

Market Signals
Indicator
JHG
BLCO
Relative Strength Index (RSI) 61.27 59.76
Support Level $45.22 $16.39
Resistance Level $46.36 $17.41
Average True Range (ATR) 0.80 0.44
MACD 0.23 0.04
Stochastic Oscillator 76.96 64.73

Price Performance

Historical Comparison
JHG
BLCO

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: